-
Pathological mechanisms of kidney disease in ageing Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-18 Takeshi Yamamoto, Yoshitaka Isaka
-
The impact of population ageing on the burden of chronic kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-18 Nicholas C. Chesnaye, Alberto Ortiz, Carmine Zoccali, Vianda S. Stel, Kitty J. Jager
-
Deep learning applications in digital pathology Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-16 Peter Boor
Deep Learning (DL) holds great promise to improve patient outcomes by improving the precision and speed of disease diagnosis and treatment recommendations. Given the efficacy of DL in image analysis, pathology will likely be one of the first medical fields transformed by DL. However, several challenges must be overcome before we can expect to see the use of DL transform the digital future of pathology
-
Treatment of chronic kidney disease in older populations Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-08 Seiji Kishi, Hiroyuki Kadoya, Naoki Kashihara
-
Application of spatial-omics to the classification of kidney biopsy samples in transplantation Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-04 Paola Tasca, Bernard M. van den Berg, Ton J. Rabelink, Gangqi Wang, Bram Heijs, Cees van Kooten, Aiko P. J. de Vries, Jesper Kers
-
The role of antibody glycosylation in autoimmune and alloimmune kidney diseases Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-03 Anaïs Beyze, Christian Larroque, Moglie Le Quintrec
-
Avenciguat reduces albuminuria in patients with chronic kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-02 Ellen F. Carney
A new study reports a beneficial effect of avenciguat — a novel, nitric oxide (NO)-independent, soluble guanylate cyclase (sGC) activator — on albuminuria in patients with chronic kidney disease (CKD). These findings were presented at the 61st European Renal Association Congress in Stockholm. In patients with CKD, insufficient production of NO leads to impairment of NO–sGC–cyclic guanosine monophosphate
-
Regulation of kidney fibrosis by ILC3s via a gut–kidney axis Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-02 Susan J. Allison
Innate lymphoid cells (ILCs) are lymphocytes that regulate immune responses. Little is known about these cells in the kidney. New findings now reveal a role for group 3 ILCs (ILC3s) in regulating kidney fibrosis, following their migration from the intestine via a CXCR6–CXCL16 signalling axis. Using single-cell RNA sequencing of genetic models combined with structural predictions of molecular interactions
-
A pre-specified analysis of the SELECT trial suggests a kidney benefit of semaglutide in patients without diabetes Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-07-02 Ellen F. Carney
Recent data from a pre-specified analysis of the SELECT trial show a beneficial effect of the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide on kidney outcomes in patients with cardiovascular disease and overweight or obesity without diabetes. These findings were presented at the 61st European Renal Association Congress in Stockholm. The SELECT trial, which included 17,604 participants
-
Natural killer cell-mediated innate microvascular rejection Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-19 Olivier Thaunat
-
Unlocking the benefits of transplantation with kidneys from older donors Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-18 Vidya A. Fleetwood, Krista L. Lentine
Kidneys from older donors might improve the quality of life and survival of patients with kidney failure, yet these organs are often underutilized. Re-framing discussions of organ acceptance from older donors and its benefits over dialysis, especially for older patients and those who cannot tolerate prolonged waiting for transplantation, is urgently needed.
-
Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-18 Katarina Zeder, Edward D. Siew, Gabor Kovacs, Evan L. Brittain, Bradley A. Maron
-
Healthy ageing and the kidney — lessons from centenarians Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-17 Yasumichi Arai, Motoko Yanagita
-
Gene regulatory networks in disease and ageing Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-12 Paula Unger Avila, Tsimafei Padvitski, Ana Carolina Leote, He Chen, Julio Saez-Rodriguez, Martin Kann, Andreas Beyer
-
Chronic kidney disease in American Indians and Alaska Natives Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-07 Vallabh O. Shah, Tassy Parker, Giselle Rodriguez de Sosa, Mark L. Unruh
-
Home monitoring of patients with chronic kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-04 Sabine H. Josemans, Lucas Lindeboom, Karin G. F. Gerritsen, Fokko P. Wieringa, Jeroen P. Kooman, Joris I. Rotmans
-
Cystatin C and the misdiagnosis of CKD in older adults Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-06-03 Andrew D. Rule, Richard J. Glassock
-
Mutational signatures of ccRCC vary between geographical regions Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-31 Ellen F. Carney
Known risk factors, such as smoking, obesity and hypertension, do not explain variations in the incidence of clear cell renal cell carcinoma (ccRCC) between different geographical regions. A new study reports that the somatic mutation profiles of ccRCC differ between countries, which indicates substantial geographical variations in mutagenic exposures. To investigate mutational signatures in ccRCC
-
VHL loss attracts immune cells to tumours Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-31 Monica Wang
VHL loss is common in clear cell renal cell carcinoma (ccRCC) and triggers a pseudohypoxic state in mutated cells. A study by Jeffrey Rathmell and colleagues now suggests that Vhl deletion also affects the tumour immune-cell infiltrate in RCC. The myeloid cells that infiltrated Vhl−/− tumours were also functionally distinct from those in control tumours, as they were more phagocytic ex vivo and had
-
Remodelling by macula densa cells Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-30 Susan J. Allison
Cells of the macula densa (MD) sense changes in tubular fluid to control functions such as renal blood flow and renin release. New findings identify a broader role for MD cells in the remodelling of kidney tissue. “The identified cell … features … suggest that the MD is a much more complex and key sensory and regulatory cell type in the nephron than previously thought,” say the researchers. To study
-
Sleep disorders in chronic kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-24 Owen D. Lyons
-
Kidney health within the broader non-communicable disease agenda Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-17 Slim Slama, Valerie A. Luyckx, Bianca Hemmingsen
Kidney disease is strongly linked with cardiovascular diseases, hypertension, diabetes, infections and other health conditions, as well as social determinants of health and climate change. Consequently, a holistic approach to promote well-being, protect individual health and improve access to quality primary care will support kidney health.
-
Podocyte-targeted therapies — progress and future directions Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-09 Kristin Meliambro, John C. He, Kirk N. Campbell
-
Spatial transcriptomics in health and disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-08 Sanjay Jain, Michael T. Eadon
-
A patient perspective on kidney disease in the public health agenda Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-05-07 Daniel Gallego
Chronic kidney disease is a life-changing diagnosis for millions of people worldwide, as the risk of disease progression and kidney failure creates unbearable uncertainty and limits lifestyle. The devastating impact of advanced kidney disease must be acknowledged in the public health agenda to pave way for improved outcomes for patients at all stages of disease.
-
Role of the gut microbiota in the pathogenesis of IgA nephropathy Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-29 Ellen F. Carney
The microbiome can modulate immune responses and has an important effect on human health, but its potential causal role in acquired autoimmune diseases remains to be determined. Now, James Gleeson, Renato Monteiro and colleagues report a mechanism by which gut microbial dysbiosis could contribute to the pathogenesis of IgA nephropathy (IgAN). As the mucin layer on the luminal side of the gut wall contains
-
Progression and outcomes of rare kidney diseases Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-26 Susan J. Allison
To describe kidney and patient outcomes for individuals with rare diseases in the UK, Gale and colleagues analysed data from 27,285 patients with 28 different types of rare kidney disease in RaDaR. Over a median follow-up of 9.6 years, RaDaR participants had a significantly higher 5-year cumulative incidence of kidney failure than that of 2.81 million patients with all-cause CKD (28% versus 1%; P < 0
-
Applications of SGLT2 inhibitors beyond glycaemic control Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-26 Daniel V. O’Hara, Carolyn S. P. Lam, John J. V. McMurray, Tae Won Yi, Samantha Hocking, Jessica Dawson, Smriti Raichand, Andrzej S. Januszewski, Meg J. Jardine
-
Post-translational modifications in kidney diseases and associated cardiovascular risk Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-25 Heidi Noels, Vera Jankowski, Stefan J. Schunk, Raymond Vanholder, Sahir Kalim, Joachim Jankowski
-
Not every organ ticks the same Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-24 Khaoula Talbi, Anette Melk
-
Immune mechanisms in the pathophysiology of hypertension Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-24 Bianca A. Nguyen, Matthew R. Alexander, David G. Harrison
-
Considerations of sex as a binary variable in clinical algorithms Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-23 Dinushika Mohottige, Samira Farouk, Tonia Poteat, Asa Radix, Selma Feldman Witchel
Clinical algorithms that are used to guide medical decision-making often include sex as a variable. However, binary considerations of sex and/or gender might introduce bias due to potentially inaccurate assumptions about sex and gender-specific physiology, hormones and exposures. An equity-focused approach to sex and gender is essential when using clinical algorithms to ensure health equity across
-
Calcium signalling and transport in the kidney Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-19 Alexander Staruschenko, R. Todd Alexander, Michael J. Caplan, Daria V. Ilatovskaya
-
Thiazides in kidney transplant recipients: skin in the game Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-17 Steven Van Laecke
-
Epithelial cell states associated with kidney and allograft injury Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-17 Christian Hinze, Svjetlana Lovric, Philip F. Halloran, Jonathan Barasch, Kai M. Schmidt-Ott
-
Kidney disease: a global health priority Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-03
The prevalence of kidney disease and its associated morbidity and mortality continue to rise. This crisis cannot be tackled unless kidney disease is made a global public health priority.
-
A new era in the science and care of kidney diseases Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-04 Carmine Zoccali, Francesca Mallamaci, Liz Lightstone, Vivek Jha, Carol Pollock, Katherine Tuttle, Peter Kotanko, Andrzej Wiecek, Hans Joachim Anders, Giuseppe Remuzzi, Kamyar Kalantar-Zadeh, Adeera Levin, Raymond Vanholder
Notable progress in basic, translational and clinical nephrology research has been made over the past five decades. Nonetheless, many challenges remain, including obstacles to the early detection of kidney disease, disparities in access to care and variability in responses to existing and emerging therapies. Innovations in drug development, research technologies, tissue engineering and regenerative
-
Combination therapy for kidney disease in people with diabetes mellitus Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-03 Daniël H. van Raalte, Petter Bjornstad, David Z. I. Cherney, Ian H. de Boer, Paola Fioretto, Daniel Gordin, Frederik Persson, Sylvia E. Rosas, Peter Rossing, Jennifer A. Schaub, Katherine Tuttle, Sushrut S. Waikar, Hiddo J. L. Heerspink
Diabetic kidney disease (DKD), defined as co-existing diabetes and chronic kidney disease in the absence of other clear causes of kidney injury, occurs in approximately 20–40% of patients with diabetes mellitus. As the global prevalence of diabetes has increased, DKD has become highly prevalent and a leading cause of kidney failure, accelerated cardiovascular disease, premature mortality and global
-
Chronic kidney disease and the global public health agenda: an international consensus Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-03 Anna Francis, Meera N. Harhay, Albert C. M. Ong, Sri Lekha Tummalapalli, Alberto Ortiz, Agnes B. Fogo, Danilo Fliser, Prabir Roy-Chaudhury, Monica Fontana, Masaomi Nangaku, Christoph Wanner, Charu Malik, Anne Hradsky, Dwomoa Adu, Sunita Bavanandan, Ana Cusumano, Laura Sola, Ifeoma Ulasi, Vivekanand Jha
Early detection is a key strategy to prevent kidney disease, its progression and related complications, but numerous studies show that awareness of kidney disease at the population level is low. Therefore, increasing knowledge and implementing sustainable solutions for early detection of kidney disease are public health priorities. Economic and epidemiological data underscore why kidney disease should
-
The global landscape of kidney registries: immense challenges and unique opportunities Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-04-02 Christopher H. Grant, Fergus J. Caskey, M. Razeen Davids, Manisha Sahay, Aminu K. Bello, Dorothea Nitsch, Samira Bell
Kidney registries are essential to understanding the burden of kidney disease and facilitating the development of sustainable and effective programs for kidney disease prevention and care. Key barriers to implementation of registries at a global scale include funding and data quality. These issues warrant the attention of the global nephrology community.
-
Sex differences in kidney metabolism and DKD Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-28 Ellen F. Carney
The epidemiology of diabetic kidney disease (DKD) differs by sex, with a greater risk of kidney failure in men. New data suggest that sex differences in kidney metabolism may contribute to these differing outcomes. In adults with chronic kidney disease, increased plasma levels of TCA cycle metabolites positively associated with male sex, diabetes and all-cause mortality and negatively associated with
-
Clonal haematopoiesis and AKI Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-26 Susan J. Allison
Clonal haematopoiesis of indeterminate potential (CHIP) arises from the clonal expansion of a mutated haematopoietic stem cell. CHIP affects 10–20% of individuals aged ≥65 years and is associated with increased mortality, although only a small proportion of patients with CHIP progress to overt haematological cancer. Now, Caitlyn Vlasschaert and colleagues demonstrate that CHIP is associated with the
-
Switching off SOX9 for epithelial recovery after AKI Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-26 Monica Wang
In acute kidney injury (AKI), dysregulated tissue regeneration can promote fibrosis and chronic kidney disease. Sustained SOX9 expression after AKI is a key promoter of fibrosis, according to a new study by Sanjeev Kumar and colleagues. Epigenetic analyses suggest that cells with persistent SOX9 expression have a progenitor cell-like phenotype with patterns of chromatin reorganization that are associated
-
Drug stewardship in chronic kidney disease to achieve effective and safe medication use Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-15 Rasheeda K. Hall, Rümeyza Kazancıoğlu, Teerawat Thanachayanont, Germaine Wong, Dharshana Sabanayagam, Marisa Battistella, Sofia B. Ahmed, Lesley A. Inker, Erin F. Barreto, Edouard L. Fu, Catherine M. Clase, Juan J. Carrero
-
Role of biophysics and mechanobiology in podocyte physiology Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-05 Jonathan Haydak, Evren U. Azeloglu
-
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-05 Djalila Mekahli, Roman-Ulrich Müller, Matko Marlais, Tanja Wlodkowski, Stefanie Haeberle, Marta López de Argumedo, Carsten Bergmann, Luc Breysem, Carla Fladrowski, Elizabeth P. Henske, Peter Janssens, François Jouret, John Christopher Kingswood, Jean-Baptiste Lattouf, Marc Lilien, Geert Maleux, Micaela Rozenberg, Stefan Siemer, Olivier Devuyst, Franz Schaefer, David J. Kwiatkowski, Olivier Rouvière
-
Innovating dialysis through computational modelling of hollow-fibre haemodialysers Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-03-04 Ruhit Sinha, Michael V. Rocco, Pirouz Daeihagh, Anne E. Staples
Haemodialyser technology has not advanced much in decades, despite its unresolved shortcomings. Sophisticated new computational tools such as high-fidelity surrogate in silico dialyser models could reduce the time and expense of exploring alternative designs, dialysis dose and operating conditions compared with the current gold standard in vitro studies.
-
Long-term health outcomes associated with hydration status Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-26 Natalia I. Dmitrieva, Manfred Boehm, Paul H. Yancey, Sofia Enhörning
-
The renal glucagon receptor is essential to kidney metabolic and homeostatic functions Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-29 Ellen F. Carney
Kidney glucagon receptors (GCGRs) are expressed along the nephron and downregulated in chronic kidney disease (CKD); however, their physiological functions are not well understood. A study by Philipp Scherer and colleagues provides insights into the roles of GCGRs in normal kidney function and in disease development. The researchers report that adult mice with constitutive or inducible kidney-specific
-
A CAAR NK cell approach to eliminate pathogenic autoantibody-secreting cells Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-28 Ellen F. Carney
Binding of autoantibodies to autoantigens expressed on podocytes causes membranous nephropathy. New findings suggest that chimeric autoantibody receptor (CAAR) natural killer (NK) cells could be used to eliminate pathogenic autoantibody-producing cells in this disease. The researchers conclude that CAAR NK and T cells can eliminate antibody-secreting target cells in an antigen-specific manner, demonstrating
-
Physiological principles underlying the kidney targeting of renal nanomedicines Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-26 Yingyu Huang, Xuhui Ning, Samira Ahrari, Qi Cai, Nilum Rajora, Ramesh Saxena, Mengxiao Yu, Jie Zheng
-
Organ trafficking — a continuing challenge Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-26 Thomas F. Mueller, Sanjay Nagral
Global inequities and inequalities, human and health-care crises, transplantation successes in the face of limited organ availability, and desperate donors and recipients underlie the backstory of organ trafficking, namely the exploitation of the most vulnerable. Despite the framework set out by the Declaration of Istanbul for the ethical donation and transplantation of organs, organ trafficking remains
-
Pericyte–stem cell crosstalk in ccRCC Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-26 Susan J. Allison
The cells that surround tumours can influence tumour growth and response to therapy. In new research, ChuanJie Zhang and colleagues report the identification of a subset of pericytes that sustain the proliferation of cancer stem cells (CSCs) in clear cell renal cell carcinoma (ccRCC) and promote tumour resistance to tyrosine kinase inhibitors (TKIs). PDGFRβ+GPR91+ pericytes, identified by single-cell
-
Sirtuins in kidney health and disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-06 Luca Perico, Giuseppe Remuzzi, Ariela Benigni
-
Macrophages clean out the tubules Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-02-01 Monica Wang
Urine supersaturation can lead to intraluminal accumulation of mineral crystals and kidney stone formation. A study by Xiao Z. Shen and colleagues now shows how juxtatubular macrophages keep these particles in check.
-
Design of a renal-sparing antifungal Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-01-30 Susan J. Allison
AmB kills fungi through the formation of large sponge-like aggregates that remove ergosterol from the cell membrane of fungi. However, Arun Maji and colleagues found that as well as removing ergosterol, AmB also removes cholesterol — a sterol that demonstrates similarities to ergosterol and is essential for normal functioning of the cell membrane — from the membranes of kidney cells. A series of investigations
-
Effects of SGLT2 inhibitors on the metabolic environment and uraemic toxins Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-01-30 Ellen F. Carney
Sodium–glucose co-transporter 2 (SGLT2) inhibitors have kidney and cardiovascular protective effects in individuals with and without diabetes. A multi-omics study provides insights into the mechanisms.
-
A united vision for cardiovascular–kidney–metabolic health Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-01-29 Susan E. Quaggin, Benjamin Magod
Improved understanding of the interrelated nature of cardiovascular, kidney and metabolic (CKM) health, the development of novel risk prediction equations, and the availability of powerful new therapies provide an opportunity to change the course of CKM health. Achieving such change at a population level will require additional advances to deliver equitable interdisciplinary care.
-
The multifaceted links between hearing loss and chronic kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-01-29 Dina Greenberg, Norman D. Rosenblum, Marcello Tonelli
-
The changing landscape of HIV-associated kidney disease Nat. Rev. Nephrol. (IF 28.6) Pub Date : 2024-01-25 Nina E. Diana, Saraladevi Naicker